Document Type
Oral Presentation
Location
Oxford Conference Center, Oxford MS
Event Website
https://oxfordicsb.org/
Start Date
8-4-2025 3:15 PM
Description
The FDA Modernization Act 2.0, emphasizes the urgent need for New Approach Methodologies (NAMs) to replace conventional animal testing in safety and efficacy assessments. NemaLife’s organism-on-chip platform, utilizing C. elegans, microfluidics and visual AI, provides a high throughput platform for in vivo screening. To enhance human relevance and reduce the inter-species gap between C. elegans and human, we developed BioSeq, a novel discovery workflow, based on high-throughput transcriptomics. Leveraging the 60-80% homology between C. elegans and human genomes, BioSeq translates worm gene expression data to human orthologs. This enables: (i) identification of differentially expressed human-relevant genes triggered by bioactive ingredients (ii) elucidation of mode-of-action pathways responsible for observed biological effects and (iii) insights into level of gene expression in human-relevant organs thereby informing on biodistribution and tissue-specificity of the bioactive ingredient. To showcase the capabilities of BioSeq, at least three independent case studies will be presented involving (i) Differential biological activities of Ashwagandha- root vs. leaf (ii) a clinically validated botanical extract mixture with known efficacy and (iii) combination bioactive designed by exploiting molecular synergy between individual phytochemicals. In summary, the BioSeq platform provides researchers with a powerful tool to bridge the scientific gap between non-rodent models and human biology, accelerating the development and validation of safe and effective bioactive ingredients while aligning with the evolving regulatory landscape.
Recommended Citation
Edwards, Hunter; Qureshi, Adnan; Rahman, Mizanur; Chiriboga, Tyler; Chittiboyina, Amar; Khan, Ikhlas; and Vanapalli, Siva, "BioSeq: A molecular intelligence platform based on organism-on-chip technology for bridging data gaps between C. elegans and Humans" (2025). Oxford ICSB. 30.
https://egrove.olemiss.edu/icsb/2025_ICSB/Schedule/30
Publication Date
April 2025
Accessibility Status
Searchable text
Included in
BioSeq: A molecular intelligence platform based on organism-on-chip technology for bridging data gaps between C. elegans and Humans
Oxford Conference Center, Oxford MS
The FDA Modernization Act 2.0, emphasizes the urgent need for New Approach Methodologies (NAMs) to replace conventional animal testing in safety and efficacy assessments. NemaLife’s organism-on-chip platform, utilizing C. elegans, microfluidics and visual AI, provides a high throughput platform for in vivo screening. To enhance human relevance and reduce the inter-species gap between C. elegans and human, we developed BioSeq, a novel discovery workflow, based on high-throughput transcriptomics. Leveraging the 60-80% homology between C. elegans and human genomes, BioSeq translates worm gene expression data to human orthologs. This enables: (i) identification of differentially expressed human-relevant genes triggered by bioactive ingredients (ii) elucidation of mode-of-action pathways responsible for observed biological effects and (iii) insights into level of gene expression in human-relevant organs thereby informing on biodistribution and tissue-specificity of the bioactive ingredient. To showcase the capabilities of BioSeq, at least three independent case studies will be presented involving (i) Differential biological activities of Ashwagandha- root vs. leaf (ii) a clinically validated botanical extract mixture with known efficacy and (iii) combination bioactive designed by exploiting molecular synergy between individual phytochemicals. In summary, the BioSeq platform provides researchers with a powerful tool to bridge the scientific gap between non-rodent models and human biology, accelerating the development and validation of safe and effective bioactive ingredients while aligning with the evolving regulatory landscape.
https://egrove.olemiss.edu/icsb/2025_ICSB/Schedule/30